BACKGROUND: p53 is a well-known tumor suppressor gene involved in malignancy. Many microRNAs (miRNAs) have recently been identified as key components of p53 signaling networks, owing to the central role of p53 in many processes, these p53-regulated miRNAs may possess important role in osteosarcoma. METHODS: The expression of six p53-related miRNAs (miR-34 family [including miR-34a, 34b and 34c], miR-31, miR-192, and miR-215) in 80 pairs of osteosarcoma and corresponding noncancerous bone tissues were estimated by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR), and the associations of miRNAs expression with clinicopathological factors, p53 status, and survival of patients were analyzed. RESULTS: We found that among all six miRNAs, miR-34 family, -192, and -215 had decreased levels, whereas the level of miR-31 was increased (p<0.05) in tumor compared with corresponding noncancerous bone tissues, and miR-192/215 in patients with p53 positive expression was lower than those with negative p53. Kaplan-Meier analysis demonstrated that osteosarcoma patients with low miR-34a (P=0.000) and miR-192 (P=0.022) expression had poorer disease-free survival (DFS). Moreover, disease-free survival (DFS) was shorter for patients with low miR-34a and miR-192 expression (P=0.007) and the combination of low miR-192 with p53 positive expression (P=0.000). Furthermore, the multivariate analysis identified that low miR-34a expression, the combination of low miR-34a and miR-192 expression levels and the combination of low miR-192 with p53 positive were independent biomarkers of shorter DFS. CONCLUSIONS: Together, these results suggest that p53-associated miR-34a and miR-192 expression could be novel prognosis biomarkers for surgically treated osteosarcoma.
BACKGROUND:p53 is a well-known tumor suppressor gene involved in malignancy. Many microRNAs (miRNAs) have recently been identified as key components of p53 signaling networks, owing to the central role of p53 in many processes, these p53-regulated miRNAs may possess important role in osteosarcoma. METHODS: The expression of six p53-related miRNAs (miR-34 family [including miR-34a, 34b and 34c], miR-31, miR-192, and miR-215) in 80 pairs of osteosarcoma and corresponding noncancerous bone tissues were estimated by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR), and the associations of miRNAs expression with clinicopathological factors, p53 status, and survival of patients were analyzed. RESULTS: We found that among all six miRNAs, miR-34 family, -192, and -215 had decreased levels, whereas the level of miR-31 was increased (p<0.05) in tumor compared with corresponding noncancerous bone tissues, and miR-192/215 in patients with p53 positive expression was lower than those with negative p53. Kaplan-Meier analysis demonstrated that osteosarcomapatients with low miR-34a (P=0.000) and miR-192 (P=0.022) expression had poorer disease-free survival (DFS). Moreover, disease-free survival (DFS) was shorter for patients with low miR-34a and miR-192 expression (P=0.007) and the combination of low miR-192 with p53 positive expression (P=0.000). Furthermore, the multivariate analysis identified that low miR-34a expression, the combination of low miR-34a and miR-192 expression levels and the combination of low miR-192 with p53 positive were independent biomarkers of shorter DFS. CONCLUSIONS: Together, these results suggest that p53-associated miR-34a and miR-192 expression could be novel prognosis biomarkers for surgically treated osteosarcoma.
Authors: Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson Journal: Cancer Res Date: 2010-02-23 Impact factor: 12.701
Authors: Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin Journal: Cancer Res Date: 2012-12-11 Impact factor: 12.701
Authors: Sara A Georges; Matthew C Biery; Soo-Yeon Kim; Janell M Schelter; Jane Guo; Aaron N Chang; Aimee L Jackson; Michael O Carleton; Peter S Linsley; Michele A Cleary; B Nelson Chau Journal: Cancer Res Date: 2008-12-15 Impact factor: 12.701
Authors: Flavia Pichiorri; Sung-Suk Suh; Alberto Rocci; Luciana De Luca; Cristian Taccioli; Ramasamy Santhanam; Wenchao Zhou; Don M Benson; Craig Hofmainster; Hansjuerg Alder; Michela Garofalo; Gianpiero Di Leva; Stefano Volinia; Huey-Jen Lin; Danilo Perrotti; Michael Kuehl; Rami I Aqeilan; Antonio Palumbo; Carlo M Croce Journal: Cancer Cell Date: 2010-10-19 Impact factor: 31.743
Authors: Jonathan Krell; Adam E Frampton; Teresa Colombo; Tamara M H Gall; Alex De Giorgio; Victoria Harding; Justin Stebbing; Leandro Castellano Journal: Epigenomics Date: 2013-08 Impact factor: 4.778
Authors: G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco Journal: Clin Transl Oncol Date: 2019-04-04 Impact factor: 3.405
Authors: Zheng Li; Chao Jiang; Xingye Li; William K K Wu; Xi Chen; Shibai Zhu; Chanhua Ye; Matthew T V Chan; Wenwei Qian Journal: Cell Prolif Date: 2017-12-04 Impact factor: 6.831